ASCO GI 2024 | FLOW + SPOTLIGHT: addressing nausea + vomiting in gastric cancer treatment with 1L zolbetuximab

Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, presents an analysis of the incidence and management of nausea and vomiting (N/V) in the Phase III SPOTLIGHT (NCT03504397) and GLOW (NCT03653507) studies. These studies evaluated the efficacy of first-line zolbetuximab plus chemotherapy versus placebo plus chemotherapy in patients with CLDN18.2+, HER2-negative, locally advanced unresectable or metastatic/gastric or gastroesophageal junction adenocarcinoma. In both studies, N/V, the most common treatment-emergent adverse events in the zolbetuximab arm, were analyzed. The results indicate that a slower infusion rate and the use of antiemetic combinations may help mitigate N/V, supporting continued treatment and maximizing clinical benefit with zolbetuximab plus chemotherapy. The interview occurred at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.